Brasco Group Invest 8 Million Euro in Charles Real Estate Joint Venture Deal
22.2.2023 20:34:00 EET | Business Wire | Press release
The Brasco B.V. conglomerate is establishing a joint venture with the real estate company Charles Real Estate.
The Dutch company is thus consolidating its position in the German residential and commercial real estate market.
The Brasco Group continues on its investment tour: with its strategic investment in the joint venture with Charles Real Estate, the Dutch conglomerate is further diversifying its portfolio.
As a first step, the Brasco Group is investing EUR 8 million in the joint venture, and in the course of 2023 is planning to invest a further EUR 30 million.
Charles Real Estate, based in Berlin, has a portfolio of 550 units in Germany with a total lettable space of more than 33,000 square metres. The company's portfolio also includes a property currently under construction with a gross floor area of 16,000 square metres.
Industry insiders regard the investment as proof of the German real estate market's stability. As the coronavirus pandemic appears to have been largely overcome and the energy crisis has been less severe than initially feared, analysts see further growth potential in the German real estate market.
This is already the second investment by the Dutch group to attract attention this year: at the beginning of February, the company announced that it was investing in Mood's Clinic, a well-known manufacturer of medical cannabis.
The Brasco Group is a Dutch conglomerate and parent company of the Brasco group of companies. The Group specialises in trade and logistics, real estate development, financial services – in particular private equity – and the distribution of textiles. The main task of the parent company is to define the strategic orientation of the individual spheres of business and to promote their growth as well as the use of synergies through investment and communication.
The Dutch conglomerate relies on innovative trade concepts to remain competitive in the global and fast-moving circulation of goods and services.
The Group's core competence in the real estate sector is the purchase and management of existing high-end properties in sought-after locations within the Federal Republic of Germany.
The Brasco Group's finance division is responsible for managing and controlling the finances of subsidiaries, suppliers, partners, shareholders and investors. Only employees of the Brasco group of companies are authorised to manage finances, which ensures finances are managed securely.
The investment division of the conglomerate plays a central role in the acquisition of majority stakes: in recent decades, the company has advised on half of all global buyouts with a sales volume of more than $500 million. In addition to buy-out funds, the Brasco Group advises on other types of fund, including hedge funds, real estate funds, private equity funds and infrastructure funds. The Dutch company also advises pension fund, sovereign wealth fund and foundation managers.
More than 1,000 investment experts are associated with the company, and they accompany the investment cycle from the contract negotiation stage to planning the withdrawal.
The Brasco Group intends to float itself on the stock market at the end of 2024.
The Managing Director of the Brasco Group is Rafy Ahmed.
Rafy Ahmed is known to the public from the TV show "Lion's Den". Ahmed founded the fashion brand "Morotai" in 2017 which specialises in sportswear. In 2018, he was awarded the Founder's Prize of the State of Baden-Württemberg. In addition to his work as CEO, he is a lecturer at the International School of Management (ISM) in Stuttgart. As a successful young entrepreneur, he shows students how to start their career. The ISM Stuttgart intends to make the course he teaches an integral part of the "Global Brand & Fashion Management" degree course.
|
Language: |
English |
|
Company: |
Brasco Group |
|
Rivium Boulevard 301 beganegrond en 1e etage |
|
|
2909LK Capelle aan den IJsse |
|
|
Netherlands |
|
|
Internet: |
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230222005788/en/
Contact information
Name: Rafy Ahmed
Tel: +905337840707
Email: info@brascogroup.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Mirum Pharmaceuticals and Incyte Announce U.S. FDA Approval of Atebrioz™ (zilurgisertib) for Adult and Pediatric Patients with Fibrodysplasia Ossificans Progressiva26.9.2026 02:00:00 EEST | Press release
Mirum Pharmaceuticals, Inc. (Nasdaq:MIRM) and Incyte (Nasdaq:INCY) today announced that the U.S. Food and Drug Administration (FDA) has approved Atebrioz™ (zilurgisertib) tablets to reduce the volume of total new heterotopic ossification (HO) in adult and pediatric patients aged 12 years and older with fibrodysplasia ossificans progressiva (FOP). The recommended dose of Atebrioz is 100 mg administered orally, once daily. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260925436454/en/ “Today marks an important milestone for people living with FOP, bringing a new treatment option to adult and pediatric patients living with this devastating disease,” said Chris Peetz, Chief Executive Officer at Mirum. “At Mirum, we are driven to serve rare disease communities where the unmet need is significant and the opportunity to make a difference is profound. The approval of Atebrioz reflects what can be achieved when industry, researchers
Digital Reef Signs Offtake Agreement with Oreasoc Agriculture to Mitigate the Environmental Footprint of Data Centre Growth Through Rainforest Protection, Appointing Xange.com as Digital MRV Partner25.9.2026 22:19:00 EEST | Press release
At Climate Week NYC, Digital Reef and Oreasoc Agriculture Inc. sign an offtake agreement connecting Digital Reef’s 3.3 GW data centre pipeline with environmental assets exceeding 30 million hectares of South American Amazon rainforest, mitigating the environmental footprint of data centre growth through rainforest protection and restoration where Oreasoc works alongside local communities to protect biodiversity, develop sustainable economies and safeguard their territories. Xange.com are appointed as digital MRV technology partner to monitor the data centres and rainforest where Digital Reef will purchase verified environmental assets generated by Oreasoc, supporting the development of low-carbon data centres mitigating their environmental footprint through the protection of high-integrity natural ecosystems across the South American Amazon, whilst advancing sustainable economic development. AI and data centre demand is driving rapid growth, with the International Energy Agency project
NetApp Announces Intent to Acquire PEAK:AIO to Advance Scalable AI Infrastructure Architecture25.9.2026 16:00:00 EEST | Press release
NetApp® (NASDAQ: NTAP), the intelligent data infrastructure company, today announced its intent to acquire PEAK:AIO, a pioneer in next-generation metadata architecture and high-performance parallel file systems. The planned acquisition is expected to accelerate NetApp's AI infrastructure roadmap by augmenting metadata services and parallel namespace innovation designed to help AI clouds scale shared storage alongside growing GPU clusters. As AI becomes embedded in every enterprise workload, organizations are confronting a new challenge: traditional storage architectures were not designed for the unprecedented scale, concurrency, and performance requirements of AI factories, AI clouds, and next-generation data-intensive applications. NetApp is building an architecture that disaggregates metadata from data and enables metadata services to scale independently, creating a foundation for AI infrastructure capable of supporting trillions of files, exabyte-scale environments, and massively pa
MultiBank Group Secures Two Awards at Forex Expo Dubai 202625.9.2026 15:57:00 EEST | Press release
MultiBank Group, one of the world’s largest financial derivatives institutions, received two awards during its participation at Forex Expo Dubai 2026, held on 22 and 23 September at Dubai World Trade Centre. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260925539591/en/ MultiBank Group was named “Best Global Institutional Financial Ecosystem of the Year” and received the award for “Excellence in Global Financial Markets Innovation and Community Impact.” The Group was named “Best Global Institutional Financial Ecosystem of the Year” and received the award for “Excellence in Global Financial Markets Innovation and Community Impact.” The first award recognised the strength and breadth of MultiBank Group’s global institutional offering, which brings together trading, liquidity, technology, infrastructure, execution, market access and tailored client solutions within an integrated financial ecosystem. The second award acknowledg
Croma-Pharma Introduces saypha ® volume prime Lidocaine25.9.2026 15:04:00 EEST | Press release
Croma-Pharma introduces saypha® volume prime Lidocaine, a cross-linked hyaluronic acid dermal filler that replaces saypha® volume Lidocaine within the company's saypha® portfolio. The new product offers physicians a more versatile solution with expanded indications for both midface volumization and nasolabial folds, backed by strong clinical data. 1,2 saypha® volume prime Lidocaine demonstrated non-inferiority to comparatora in a randomized, subject- and evaluator-blinded, controlled, non-inferiority multicenter, parallel group comparison study with almost 500 patients.2 In the clinical evaluation, a high patient satisfaction highlights improved midface fullness, smoothness and contour, consistent with a rheologic profile designed to provide volumization in the mobile midface.b,2 With saypha® volume prime Lidocaine, Croma-Pharma further strengthens its product range, reflecting the company's long-standing commitment to scientific excellence and continuous product innovation, and provid
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom